Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)

Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry M. Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew J. Monberg, Coleman K. Obasaju, Mark A. Socinski

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment. Materials and methods: The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months. Results: Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI∈=∈52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining. Conclusions: Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalSupportive Care in Cancer
Volume17
Issue number3
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Quality of Life
gemcitabine
Carboplatin
Drug Therapy
Paclitaxel
Cisplatin

Keywords

  • Early stage NSCLC
  • Gemcitabine
  • Lung Cancer Symptom Scale
  • Quality of life

ASJC Scopus subject areas

  • Oncology

Cite this

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC) : Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). / Gralla, Richard J.; Edelman, Martin J.; Detterbeck, Frank C.; Jahan, Thierry M.; Loesch, David M.; Limentani, Steven A.; Govindan, Ramaswamy; Peng, Guangbin; Monberg, Matthew J.; Obasaju, Coleman K.; Socinski, Mark A.

In: Supportive Care in Cancer, Vol. 17, No. 3, 03.2009, p. 307-313.

Research output: Contribution to journalArticle

Gralla, RJ, Edelman, MJ, Detterbeck, FC, Jahan, TM, Loesch, DM, Limentani, SA, Govindan, R, Peng, G, Monberg, MJ, Obasaju, CK & Socinski, MA 2009, 'Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)', Supportive Care in Cancer, vol. 17, no. 3, pp. 307-313. https://doi.org/10.1007/s00520-008-0489-y
Gralla, Richard J. ; Edelman, Martin J. ; Detterbeck, Frank C. ; Jahan, Thierry M. ; Loesch, David M. ; Limentani, Steven A. ; Govindan, Ramaswamy ; Peng, Guangbin ; Monberg, Matthew J. ; Obasaju, Coleman K. ; Socinski, Mark A. / Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC) : Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). In: Supportive Care in Cancer. 2009 ; Vol. 17, No. 3. pp. 307-313.
@article{1b66769654f349db9098d924022ab617,
title = "Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)",
abstract = "Background: The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment. Materials and methods: The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months. Results: Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84{\%} had an ECOG performance status of 0, 93{\%} had a complete resection, and 67{\%} (95{\%} CI∈=∈52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33{\%}). These patients experienced a mean worsening of 66{\%} in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining. Conclusions: Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.",
keywords = "Early stage NSCLC, Gemcitabine, Lung Cancer Symptom Scale, Quality of life",
author = "Gralla, {Richard J.} and Edelman, {Martin J.} and Detterbeck, {Frank C.} and Jahan, {Thierry M.} and Loesch, {David M.} and Limentani, {Steven A.} and Ramaswamy Govindan and Guangbin Peng and Monberg, {Matthew J.} and Obasaju, {Coleman K.} and Socinski, {Mark A.}",
year = "2009",
month = "3",
doi = "10.1007/s00520-008-0489-y",
language = "English (US)",
volume = "17",
pages = "307--313",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC)

T2 - Results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)

AU - Gralla, Richard J.

AU - Edelman, Martin J.

AU - Detterbeck, Frank C.

AU - Jahan, Thierry M.

AU - Loesch, David M.

AU - Limentani, Steven A.

AU - Govindan, Ramaswamy

AU - Peng, Guangbin

AU - Monberg, Matthew J.

AU - Obasaju, Coleman K.

AU - Socinski, Mark A.

PY - 2009/3

Y1 - 2009/3

N2 - Background: The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment. Materials and methods: The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months. Results: Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI∈=∈52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining. Conclusions: Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.

AB - Background: The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment. Materials and methods: The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months. Results: Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI∈=∈52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining. Conclusions: Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.

KW - Early stage NSCLC

KW - Gemcitabine

KW - Lung Cancer Symptom Scale

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=59449110325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449110325&partnerID=8YFLogxK

U2 - 10.1007/s00520-008-0489-y

DO - 10.1007/s00520-008-0489-y

M3 - Article

C2 - 18781341

AN - SCOPUS:59449110325

VL - 17

SP - 307

EP - 313

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -